X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Motilal Oswal - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs MOTILAL OSWAL - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

MOTILAL OSWAL 
   Change

Motilal Oswal Financial Services (MOFSL) derives a significant portion of its revenues from equity broking (69% in FY12) for both retail and institutional clients. Accordingly, its revenues and profits are dependent on favourable capital market condi... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES MOTILAL OSWAL INDOCO REMEDIES/
MOTILAL OSWAL
 
P/E (TTM) x 23.0 44.0 52.4% View Chart
P/BV x 2.7 11.7 23.4% View Chart
Dividend Yield % 0.8 0.3 273.5%  

Financials

 INDOCO REMEDIES   MOTILAL OSWAL
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
MOTILAL OSWAL
Mar-16
INDOCO REMEDIES/
MOTILAL OSWAL
5-Yr Chart
Click to enlarge
High Rs360364 99.0%   
Low Rs249239 104.4%   
Sales per share (Unadj.) Rs119.074.2 160.4%  
Earnings per share (Unadj.) Rs8.411.9 70.3%  
Cash flow per share (Unadj.) Rs15.214.4 106.1%  
Dividends per share (Unadj.) Rs1.603.50 45.7%  
Dividend yield (eoy) %0.51.2 45.2%  
Book value per share (Unadj.) Rs70.7101.0 70.0%  
Shares outstanding (eoy) m92.15142.17 64.8%   
Bonus/Rights/Conversions -PF-  
Price / Sales ratio x2.64.1 63.1%   
Avg P/E ratio x36.425.3 143.9%  
P/CF ratio (eoy) x20.021.0 95.3%  
Price / Book Value ratio x4.33.0 144.6%  
Dividend payout %19.129.4 65.0%   
Avg Mkt Cap Rs m28,08342,829 65.6%   
No. of employees `0006.0NA 37,725.0%   
Total wages/salary Rs m2,1672,510 86.3%   
Avg. sales/employee Rs Th1,817.0659,312.5 0.3%   
Avg. wages/employee Rs Th359.0156,843.8 0.2%   
Avg. net profit/employee Rs Th127.7105,675.0 0.1%   
INCOME DATA
Net Sales Rs m10,96810,549 104.0%  
Other income Rs m40247 16.1%   
Total revenues Rs m11,00710,796 102.0%   
Gross profit Rs m1,5654,086 38.3%  
Depreciation Rs m633349 181.1%   
Interest Rs m621,738 3.6%   
Profit before tax Rs m9092,245 40.5%   
Minority Interest Rs m0-26 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139612 22.7%   
Profit after tax Rs m7711,691 45.6%  
Gross profit margin %14.338.7 36.8%  
Effective tax rate %15.327.3 55.9%   
Net profit margin %7.016.0 43.8%  
BALANCE SHEET DATA
Current assets Rs m5,72515,621 36.6%   
Current liabilities Rs m5,45419,116 28.5%   
Net working cap to sales %2.5-33.1 -7.4%  
Current ratio x1.00.8 128.4%  
Inventory Days Days620-  
Debtors Days Days72246 29.2%  
Net fixed assets Rs m5,3072,921 181.7%   
Share capital Rs m184142 129.6%   
"Free" reserves Rs m6,33112,838 49.3%   
Net worth Rs m6,51614,365 45.4%   
Long term debt Rs m1,32317,000 7.8%   
Total assets Rs m11,97050,906 23.5%  
Interest coverage x15.62.3 682.5%   
Debt to equity ratio x0.21.2 17.2%  
Sales to assets ratio x0.90.2 442.2%   
Return on assets %7.06.7 103.3%  
Return on equity %11.811.8 100.5%  
Return on capital %12.412.9 96.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,1410-   
Net fx Rs m3,3660-   
CASH FLOW
From Operations Rs m886-11,610 -7.6%  
From Investments Rs m-1,706-3,799 44.9%  
From Financial Activity Rs m1,31616,372 8.0%  
Net Cashflow Rs m497963 51.6%  

Share Holding

Indian Promoters % 59.2 74.1 79.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 7.5 166.7%  
FIIs % 6.0 5.3 113.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 13.1 171.0%  
Shareholders   12,805 11,283 113.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   FINOLEX IND.  EDELWEISS FINANCIAL  FUTURE CONSUMER  CREST VENTURES  CCL INTERNATIONAL  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Aug 21, 2017 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS